3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
2
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
250
Carcinoma, Non-Small-Cell Lung
227
Prostatic Neoplasms
118
Neoplasms
106
Multiple Myeloma
91
Neoplasm Metastasis
76
Colorectal Neoplasms
74
Parkinson Disease 4, Autosomal Dominant Lewy Body
69
Lung Neoplasms
67
Ovarian Neoplasms
61
Leukemia, Myeloid, Acute
50
Carcinoma, Hepatocellular
48
Melanoma
47
Carcinoma, Renal Cell
45
Leukemia, Lymphocytic, Chronic, B-Cell
44
Triple Negative Breast Neoplasms
42
Urinary Bladder Neoplasms
41
Stomach Neoplasms
41
Squamous Cell Carcinoma of Head and Neck
41
Recurrence
41
Brain Neoplasms
40
Myasthenia Gravis
37
Small Cell Lung Carcinoma
35
Lymphoma, Follicular
35
Nasopharyngeal Carcinoma
34
Head and Neck Neoplasms
34
Pancreatic Neoplasms
32
Rectal Neoplasms
31
Lymphoma, Large B-Cell, Diffuse
30
Endometrial Neoplasms
29
Interventions
palbociclib
1
lenvatinib
1
cabozantinib
1
belzutifan
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
von Hippel-Lindau Disease
×
1 year
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled